SFRP5 and cardiac hypertrophy: Consequently, angiotensin II increases the expression of SFRP5 in a time and dose-dependent manner, as SFRP5 inhibits the expression of natriuretic peptide b and tumor necrosis factor alpha in hypertrophic cardiomyocytes through AT1 receptor/Rho/Rock1/JNK signaling pathway, which plays an important role in the pathological process of cardiac hypertrophy (157).